Seres Therapeutics

Seres Therapeutics: Series E Funding Round

Seres Therapeutics has successfully raised $113M in Series E funding, reaching a valuation of $450M.

Company Overview

Microbiome therapeutic platform

Funding Details

The Series E round was led by Flagship Pioneering, with participation from Polaris Partners, Fidelity, Nestle Health Science, Takeda Ventures.

Company Information

• Headquarters: 200 Sidney Street, Cambridge, MA 02139
• Founded: 2010
• Employees: 250+
• Category: Biotech

Investment

Seres Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• Flagship Pioneering: Verified investor in Series E
• Polaris Partners: Verified investor in Series E
• Fidelity: Verified investor in Series E
• Nestle Health Science: Verified investor in Series E
• Takeda Ventures: Verified investor in Series E